Properties and regulation of GnRH receptors in the anterior pituitary and the testis of the rat: different response of Leydig cell LH and GnRH receptors to hormonal treatments.
The properties (association and dissociation rates, affinity and specificity) of GnRH receptors in the rat pituitary and the Leydig cells are very similar. In addition, in vivo administration for 5 or 11 days of 10 micrograms of GnRH to adult rats resulted in an increase (p less than 0.01) in both Leydig cell and pituitary GnRH receptors. In contrast, the same treatment caused a significant decrease (p less than 0.01) of Leydig cell LH receptor number. Furthermore, testosterone propionate (500 micrograms/day), which had no effect on Leydig cell LH receptors, caused a significant increase (p less than 0.01) of testicular GnRH receptors but a decrease (p less than 0.01) of pituitary GnRH receptors. Estradiol 17 beta valerate (5 micrograms/day) reduced (p less than 0.01) both testicular (5 days) and pituitary (5 and 11 days) GnRH receptors. Such treatment for 5 days also decreased (p less than 0.05) the Leydig cell LH receptors. No effect of dexamethasone and 17-hydroxyprogesterone was seen after 5 or 11 days of treatment. Thus, although pituitary and Leydig cell receptors appear similar, their regulation by exogenous hormone treatments is different. Furthermore, the regulation of Leydig cell GnRH and LH receptors also appears very different, suggesting different roles of the receptors in the control of the Leydig cell function.
D019326:17-alpha-Hydroxyprogesterone; D000818:Animals; D001665:Binding Sites; D002064:Buserelin / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology*; D006908:Hydroxyprogesterones / Q000494:pharmacology; D007700:Kinetics; D007985:Leydig Cells / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000378:metabolism*; D011974:Receptors, LH; D011966:Receptors, LHRH; D013379:Substrate Specificity; D013737:Testis / Q000187:drug effects / Q000378:metabolism*; D013739:Testosterone / Q000494:pharmacology
D006728:Hormones; D006908:Hydroxyprogesterones; D011956:Receptors, Cell Surface; D011974:Receptors, LH; D011966:Receptors, LHRH; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004958:Estradiol; C010661:surfagon; D019326:17-alpha-Hydroxyprogesterone; D003907:Dexamethasone; D002064:Buserelin